Unlikely to meet its primary objective (Il Sole 24 Ore Radiocor) - Berlin, 25 Jun - The German chemical and pharmaceutical company Merck KGaA announced the discontinuation of the phase III study of its head and neck cancer drug xevinapant.

The decision comes after an interim analysis found that the "trial would be unlikely to meet its primary objective of prolonging event-free survival." Danny Bar-Zohar, global head of research & development and chief medical officer for the Healthcare business sector, said 'while we are disappointed by these results, we remain steadfast in our commitment to develop transformative medicines within our oncology portfolio for areas of high unmet need.' Merck said that it is working to "develop and deliver new treatment options that exploit the vulnerabilities of tumor cells." The company is exploring modalities including antibody drug conjugates and DNA damage response inhibitors, across multiple tumor types, including many that have proven difficult to treat where there are significant unmet needs for patients.

AAA-Web

(RADIOCOR) 25-06-24 12:35:00 (0318) 5 NNNN